Barcelona-based Seqera Labs, which provides data orchestration and workflow software for life sciences, has raised a €22M Series A led by Lee Fixel's Addition
Dan Taylor / Tech.eu :
Context & Ripple Effects
Seqera Labs' €22M Series A lands in a funding lane that has been building since TetraScience's $80M Series B in 2021 and Artificial's $21.5M round led by Microsoft's M12 — investors are consistently paying up for the software layer that moves and structures life sciences data rather than the science itself.
The round also strengthens Barcelona's claim as a life sciences software hub: four years after this raise, the city produced Biorce's $52.5M Series A for AI-driven clinical trials, making Seqera an early marker of a regional cluster that keeps attracting US-style growth capital.
First-order effects
- Lee Fixel's Addition gives Seqera Labs the capital to scale its workflow orchestration platform against better-funded rivals like TetraScience ($88M+ total) for the same pharma and biotech data-infrastructure budgets.
- Life sciences customers now have a credible European-headquartered alternative in the orchestration layer, pressuring incumbents on integration breadth and pricing.
Second-order effects
- The wave continues downstream of Seqera: within a month, Germany's Temedica extended its Series B to €42M selling health-data insight to pharma, showing that money raised for data plumbing pulls adjacent analytics vendors into the same buyer conversations.
- Instrument makers and lab software vendors face growing pressure to open their formats and APIs, since orchestration platforms like Seqera's only win when they can sit across heterogeneous sources.
Third-order effects
- If the pattern holds — TetraScience, Artificial, Seqera, Temedica, then Biorce — the industry is structurally re-layering around a vendor-neutral data plane between laboratory systems and analysis, with platform ownership becoming the choke point for life sciences R&D workflows.
- Barcelona's repeated appearance in these rounds suggests European life sciences software can reach Series A/B scale locally before US capital arrives, reshaping where these companies are founded and stay headquartered.
The trend: Venture capital is concentrating on the data-orchestration and workflow layer of life sciences R&D, with Barcelona emerging as a recurring source of funded companies in that stack.